MedinCell S.A. (EPA:MEDCL)

Market Cap	893.48M +52.0%
Revenue (ttm)	24.28M -12.4%
Net Income	-31.29M
EPS	-0.94
Shares Out	35.91M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	41,287
Open	24.22
Previous Close	24.12
Day's Range	24.06 - 24.88
52-Week Range	16.64 - 39.68
Beta	0.98
Analysts	Strong Buy
Price Target	34.51 (+38.71%)
Earnings Date	Dec 8, 2026

About MedinCell

MedinCell S.A. engages in the research and development of biodegradable polymer-based processes for the controlled and prolonged delivery of active pharmaceutical ingredients into the human body and animals in France. The company offers UZEDY, a subcutaneous risperidone for the treatment of schizophrenia. It also develops mdc-TJK, a subcutaneous injection, which is in NDA stage for the treatment of schizophrenia; and mdc-CWM, a sustained-release formulation of celecoxib, which is in Phase III clinical trial for the treatment and reduction of po...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 141
• Stock Exchange: Euronext Paris
• Ticker Symbol: MEDCL

Financial Performance

In fiscal year 2026, MedinCell's revenue was 24.28 million, a decrease of -12.44% compared to the previous year's 27.73 million. Losses were -31.29 million, 69.7% more than in 2025.

Analyst Summary

According to 9 analysts, the average rating for MEDCL stock is "Strong Buy." The 12-month stock price target is €34.51, which is an increase of 38.71% from the latest price.

Price Target

€34.51

(38.71% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 21, 2026

Data Sources Report a data error